Bank of New York Mellon Corp raised its holdings in shares of Athersys, Inc. (NASDAQ:ATHX) by 7.3% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 284,540 shares of the biopharmaceutical company’s stock after purchasing an additional 19,375 shares during the period. Bank of New York Mellon Corp owned approximately 0.26% of Athersys worth $430,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Vanguard Group Inc. boosted its stake in Athersys by 19.5% during the 1st quarter. Vanguard Group Inc. now owns 3,899,200 shares of the biopharmaceutical company’s stock valued at $6,668,000 after purchasing an additional 637,322 shares during the last quarter. Wells Fargo & Company MN boosted its stake in Athersys by 4.8% during the 1st quarter. Wells Fargo & Company MN now owns 61,176 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 2,800 shares during the last quarter. Geode Capital Management LLC boosted its stake in Athersys by 35.2% during the 1st quarter. Geode Capital Management LLC now owns 756,004 shares of the biopharmaceutical company’s stock valued at $1,292,000 after purchasing an additional 196,981 shares during the last quarter. NEXT Financial Group Inc boosted its stake in Athersys by 3.2% during the 2nd quarter. NEXT Financial Group Inc now owns 97,950 shares of the biopharmaceutical company’s stock valued at $148,000 after purchasing an additional 3,000 shares during the last quarter. Finally, Bank of America Corp DE boosted its stake in Athersys by 17.2% during the 1st quarter. Bank of America Corp DE now owns 61,580 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 9,019 shares during the last quarter. Institutional investors and hedge funds own 19.15% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Athersys, Inc. (ATHX) Holdings Increased by Bank of New York Mellon Corp” was originally published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://theolympiareport.com/2017/11/01/athersys-inc-athx-holdings-increased-by-bank-of-new-york-mellon-corp.html.

In other news, EVP John J. Harrington sold 15,000 shares of the business’s stock in a transaction on Monday, September 18th. The shares were sold at an average price of $2.17, for a total transaction of $32,550.00. Following the sale, the executive vice president now directly owns 679,416 shares of the company’s stock, valued at $1,474,332.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 9.40% of the stock is owned by insiders.

Several analysts have commented on ATHX shares. Zacks Investment Research downgraded Athersys from a “buy” rating to a “hold” rating in a research note on Thursday, August 31st. Maxim Group set a $12.00 target price on Athersys and gave the company a “buy” rating in a research note on Monday, August 7th. Finally, ValuEngine upgraded Athersys from a “sell” rating to a “hold” rating in a research note on Friday, September 15th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the stock. Athersys currently has a consensus rating of “Hold” and a consensus price target of $7.17.

Shares of Athersys, Inc. (ATHX) opened at 1.84 on Wednesday. The firm’s 50-day moving average price is $2.17 and its 200 day moving average price is $1.72. Athersys, Inc. has a 52 week low of $1.02 and a 52 week high of $2.63. The stock’s market capitalization is $209.60 million.

Athersys (NASDAQ:ATHX) last announced its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.06). The firm had revenue of $0.67 million for the quarter, compared to analyst estimates of $0.96 million. Athersys had a negative net margin of 729.07% and a negative return on equity of 121.47%. The business’s quarterly revenue was up 12.4% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.08) earnings per share. Analysts expect that Athersys, Inc. will post ($0.24) earnings per share for the current year.

About Athersys

Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.

Want to see what other hedge funds are holding ATHX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Athersys, Inc. (NASDAQ:ATHX).

Institutional Ownership by Quarter for Athersys (NASDAQ:ATHX)

Receive News & Ratings for Athersys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.